The Mohali unit of Sun Pharma inspection got completed last week and 2-3 observations were undertaken by US FDA, reports CNBC-TV18’s Ekta Batra quoting sources.The inspection was largely positive in the large scheme of things because the Mohali unit was under an import alert since 2013 and wasn’t contributing financially to Sun Pharma or Ranbaxy. Meanwhile, sources also say that USFDA has begun re-inspection of the Halol unit.Wockhardt, Sun Pharma, Tara, Novartis and other pharma company Perrigo are also in focus on account of reports from the US that there are lawsuits filed by Unions representing the New York Police Department on price collusion of two dermatology products. The allegation is that they have raised prices by around 1000 percent in the last couple of years.Companies like Taro are facing an anti-trust probe by the US Justice Department, say sources.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!